42 Directors report FOR THE YEAR ENDED 31 DECEMBER 2003 The Directors report on the affairs of the Group is presented below.
The Group financial statements and auditors report for the year ended 31 December 2003 are presented within this document.
PRINCIPAL ACTIVITIES AND BUSINESS REVIEW A review of the business and future developments of the Group is set out on pages 1 to 25.
The principal activities of the Group are the research, development, manufacture and sale of vaccines to prevent and treat infectious diseases.
RESULTS AND DIVIDENDS The profit for the year after taxation amounted to 35.5m 2002 9.6m.
The Directors do not recommend a final dividend for the year 2002 nil.
In the year ended 31 December 2003, the Group generated revenues of 169.1m 2002 79.7m.
Further details of the results for the year and future developments for the Group are set out on pages 14 to 25.
RESEARCH AND DEVELOPMENT R&D The Group incurred R&D costs of 19.9m 2002 16.5m during the year, which have been written off to the profit and loss account in accordance with the Groups accounting policy.
DIRECTORS AND THEIR INTERESTS The Directors who served during 2003 are shown on page 27.
The interests of the Directors in the Companys shares and options to purchase shares in the Company are shown in the remuneration report on pages 34 to 41.
At 31 December 2003, the Directors held an aggregate 988,309 shares, representing 0.9% of the current issued capital.
None of the Directors had an interest in a contract of significance to which the Company or any of its subsidiary undertakings was party during the year.
POLICY ON PAYMENT OF CREDITORS It is the Groups policy that payments to suppliers be made in accordance with those terms and conditions agreed between the Group and its suppliers, provided that all trading terms and conditions have been met.
At 31 December 2003, the Company had an average of 13 days 2002 21 days of purchases outstanding in trade creditors.
At 31 December 2003, the Group had an average of 67 days 2002 178 days of purchases outstanding in trade creditors.
In 2002, the number included outstanding trade creditors payable to Baxter, which, under the terms of Acambis agreement with Baxter, Acambis was not required to pay until it had been paid by the US CDC.
Excluding these amounts payable to Baxter in 2002, the Group had an average of 66 days of purchases outstanding in trade creditors.
CORPORATE SOCIAL RESPONSIBILITY The Directors recognise the increasing importance of Corporate Social Responsibility and as a result have included a report on its current activities in this area on pages 20 and 21.
POLITICAL AND CHARITABLE DONATIONS During the year, the Group made contributions amounting to 6,525 2002 880.
Of this total, 2,996 related to medical research, 2,666 for the biotechnology industry, 663 to childrens charities and 200 to local charities.
No political donations were made during the year 2002 nil.
Employees participated in various charitable fundraising activities during the year in aid of local and national charities.
EMPLOYEES Acambis seeks to involve its employees in its corporate objectives, plans, performance and on other relevant matters of interest to employees through various communication methods, including regular Company meetings.
Employees of Acambis are not part of any labour unions.
The Directors consider there to be a good relationship between employees and management.
The Group is an equal opportunities employer and does not discriminate in the recruitment and promotion of staff, including applicants who are disabled.
If an employee becomes disabled it is the policy, wherever practicable, to provide continued employment.
All employees are encouraged to share in the growth of the Group, being eligible to participate in share option schemes.
